Impact of SARS-CoV-2 Pandemic on the Management of Patients with Hepatocellular Carcinoma

Academic Article

Publication Date:

2022

Short description:

Maria, G., Valentina, C., Mario, C., Chiara, M., Filippo, P., Rodolfo, S., Francesco Paolo, R., Alessandro, V., Franco, T., Giuseppe, C., Baccarani, U., Bhoori, S., Borzio, M., Brancaccio, G., Burra, P., Casadei Gardini, A., Carrai, P., Centonze, L., Cescon, M., Cillo, U., Cozzolongo, R., Cucchetti, A., De Matthaeis, N., Di Costanzo, G. G., Di Sandro, S., Famularo, S., Farinati, F., Finotti, M., Giuseppe Foschi, F., Galati, G., Gambato, M., Giovanni Giannini, E., Giuliante, F., Ghinolfi, D., Gruttaduria, S., Iavarone, M., Kostandini, A., Lai, Q., Lenci, I., Giovanni Lupo, L., Manzia, T., Marasco, G., Marenco, S., Masarone, M., Mazzocato, S., Melandro, F., Mescoli, C., Miele, L., Morisco, F., Nicolini, D., Pagano, D., Persico, M., Platz Torres, M. C., Ponziani, F. R., Pravisani, R., Rendina, M., Renzulli, M., Ricci, L., Romano, F., Battista Levi Sandri, G., Sangiovanni, A., Sposito, C., Tortora, R., Viganò, L., Viganò, M., Vincenzi, V., Violi, P., Impact of SARS-CoV-2 Pandemic on the Management of Patients with Hepatocellular Carcinoma, <>, 2022; 11 (15): N/A-N/A. [doi:10.3390/jcm11154475] [https://hdl.handle.net/10807/245014]

abstract:

Worldwide, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) significantly increases mortality and morbidity. The Coronavirus Disease 2019 (COVID-19) outbreak has had a considerable impact on healthcare systems all around the world, having a significant effect on planned patient activity and established care pathways, in order to meet the difficult task of the global pandemic. Patients with hepatocellular carcinoma (HCC) are considered a particularly susceptible population and conceivably at increased risk for severe COVID-19 because of two combined risk factors: chronic advanced liver disease and HCC itself. In these challenging times, it is mandatory to reshape clinical practice in a prompt way to preserve the highest standards of patient care and safety. However, due to the stay-at-home measures instituted to stop the spread of COVID-19, HCC surveillance has incurred a dramatic drop, and care for HCC patients has been rearranged by refining the algorithm for HCC treatment to the COVID-19 pandemic, permitting these patients to be safely managed by identifying those most at risk of neoplastic disease progression.

Iris type:

Articolo in rivista, Nota a sentenza

Keywords:

COVID-19; SARS-CoV-2; hepatocellular carcinoma; liver cancer

List of contributors: